A major international study is questioning one of the oldest and most routine treatments given after a heart attack.
Researchers say many patients with uncomplicated heart attacks and normal heart function may not benefit from beta blockers, a class of drugs that has been standard treatment for decades.
The findings come from the REBOOT Trial, a large clinical study led by researchers from Mount Sinai Fuster Heart Hospital and Spain’s Centro Nacional de Investigaciones Cardiovasculares.
The results were presented at the European Society of Cardiology Congress and published in The New England Journal of Medicine.
Beta blockers have been widely used since the late 20th century to help protect the heart after a heart attack. These drugs work by slowing the heartbeat and lowering blood pressure, which reduces strain on the heart.
In earlier decades, heart attack patients faced much higher risks of dangerous heart rhythms, severe heart damage, and death because treatment options were limited. Beta blockers helped reduce those risks and became a standard part of care worldwide.
But heart attack treatment has changed dramatically over the years.
Today, blocked arteries are often reopened quickly through emergency procedures such as angioplasty and stenting. Patients also receive modern medications including statins, blood thinners, and advanced therapies that greatly reduce complications.
Because of these improvements, scientists have begun to wonder whether beta blockers still provide extra benefits for patients who recover well and maintain normal heart pumping function.
The REBOOT Trial was created to investigate this question.
Researchers enrolled 8,505 patients from hospitals across Spain and Italy. All participants had experienced relatively uncomplicated heart attacks and still had preserved heart function after treatment.
After leaving the hospital, some patients were prescribed beta blockers while others were not. Researchers then followed them for almost four years.
The results showed no significant difference between the two groups in rates of death, repeat heart attacks, or hospitalization for heart failure.
For a medication used so routinely for so many years, the findings could have major consequences for future medical guidelines.
Researchers say the study may eventually help reduce unnecessary medication use after heart attacks.
Although beta blockers are generally considered safe, they can cause side effects such as tiredness, dizziness, slow heart rate, depression, and sexual dysfunction. Some patients also struggle to take many medications every day after a heart attack.
Reducing unnecessary medicines may improve comfort, simplify recovery, and increase treatment adherence.
The study also identified a potentially important issue involving women.
A separate analysis published in the European Heart Journal found that women with normal heart function who received beta blockers had a slightly higher risk of death, another heart attack, or hospitalization for heart failure compared with women who did not receive the medication.
Researchers emphasized that these findings should not cause patients to stop their medications without medical advice. Instead, they suggest that doctors may need to reconsider whether all patients benefit equally from beta blockers.
At the same time, scientists stress that beta blockers still remain very important for many people. Patients with weakened heart function, irregular heart rhythms, high blood pressure, or other heart conditions may still gain major benefits from these drugs.
The study highlights a broader trend in modern medicine toward personalized treatment. Instead of automatically giving the same medications to every patient, doctors are increasingly trying to identify which therapies truly help specific groups of people.
Other recent studies have also questioned routine beta blocker use after heart attacks. The REDUCE-AMI trial published in 2024 reported similar findings in patients with preserved heart function.
However, some newer trials suggest that patients with mildly reduced heart function may still benefit from beta blockers. Researchers say this means future treatment guidelines may become more selective rather than completely abandoning the drugs.
The REBOOT researchers say their goal is not to remove useful treatments, but to ensure patients receive medications supported by strong modern evidence.
Looking carefully at the study, the findings appear highly important because they challenge a medical practice that has been accepted for more than four decades. The trial was large, international, and carefully designed, which gives the results considerable scientific weight.
However, medicine is rarely one-size-fits-all, and the evidence also shows that some patients may still benefit from beta blockers depending on their heart function and overall risk.
The research reflects a growing movement in healthcare toward more individualized treatment decisions rather than automatically continuing older practices simply because they have been used for many years.
If future studies confirm these findings, doctors may eventually prescribe beta blockers more selectively, helping patients avoid unnecessary side effects while still protecting those who truly need the medication.
